title: Contribution of new technologies to characterization and prediction of adverse effects.
abstract: Identification of the potential hazards of chemicals has traditionally relied on studies in laboratory animals where changes in clinical pathology and histopathology compared to untreated controls defined an adverse effect. In the past decades, increased consistency in the definition of adversity with chemically-induced effects in laboratory animals, as well as in the assessment of human relevance has been reached. More recently, a paradigm shift in toxicity testing has been proposed, mainly driven by concerns over animal welfare but also thanks to the development of new methods. Currently, in vitro approaches, toxicogenomic technologies and computational tools, are available to provide mechanistic insight in toxicological Mode of Action (MOA) of the adverse effects observed in laboratory animals. The vision described as Tox21c (Toxicity Testing in the 21st century) aims at predicting in vivo toxicity using a bottom-up-approach, starting with understanding of MOA based on in vitro data to ultimately predict adverse effects in humans. At present, a practical application of the Tox21c vision is still far away. While moving towards toxicity prediction based on in vitro data, a stepwise reduction of in vivo testing is foreseen by combining in vitro with in vivo tests. Furthermore, newly developed methods will also be increasingly applied, in conjunction with established methods in order to gain trust in these new methods. This confidence is based on a critical scientific prerequisite: the establishment of a causal link between data obtained with new technologies and adverse effects manifested in repeated-dose in vivo toxicity studies. It is proposed to apply the principles described in the WHO/IPCS framework of MOA to obtain this link. Finally, an international database of known MOAs obtained in laboratory animals using data-rich chemicals will facilitate regulatory acceptance and could further help in the validation of the toxicity pathway and adverse outcome pathway concepts.
authors.affiliation: Bayer CropScience , Sophia Antipolis , France.
authors.forename: David
authors.initials: D
authors.lastname: Rouquié
authors.forename: Marjoke
authors.initials: M
authors.lastname: Heneweer
authors.forename: Jane
authors.initials: J
authors.lastname: Botham
authors.forename: Hans
authors.initials: H
authors.lastname: Ketelslegers
authors.forename: Lauren
authors.initials: L
authors.lastname: Markell
authors.forename: Thomas
authors.initials: T
authors.lastname: Pfister
authors.forename: Winfried
authors.initials: W
authors.lastname: Steiling
authors.forename: Volker
authors.initials: V
authors.lastname: Strauss
authors.forename: Christa
authors.initials: C
authors.lastname: Hennes
mesh_terms: D000826:Animal Testing Alternatives; D000818:Animals; D004353:Drug Evaluation, Preclinical; D064420:Drug-Related Side Effects and Adverse Reactions / Q000209:etiology* / Q000235:genetics; D006801:Humans; D011237:Predictive Value of Tests; D018570:Risk Assessment; D018675:Toxicity Tests / Q000379:methods*; D043922:Toxicogenetics / Q000379:methods*
keywords: adverse effect; in vitro testing; mode of action; omics; predictive toxicology